Publication: Prevalence of Cervical High-risk Human Papilloma Viral Infection in Pregnant Women at HRH Maha Chakri Sirindhorn Medical Center, Thailand
2
0
Issued Date
2024-03-01
Resource Type
ISSN
08576084
eISSN
26730871
Scopus ID
2-s2.0-85187712371
Journal Title
Thai Journal of Obstetrics and Gynaecology
Volume
32
Issue
2
Start Page
128
End Page
136
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thai Journal of Obstetrics and Gynaecology Vol.32 No.2 (2024) , 128-136
Suggested Citation
Kulpornsirikul M., Srison U., Laosooksathit W., Tantitamit T. Prevalence of Cervical High-risk Human Papilloma Viral Infection in Pregnant Women at HRH Maha Chakri Sirindhorn Medical Center, Thailand. Thai Journal of Obstetrics and Gynaecology Vol.32 No.2 (2024) , 128-136. 136. Retrieved from: https://hdl.handle.net/20.500.14740/20189
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: To determine the prevalence of high-risk human papilloma viral (HR-HPV) infection and the factors associated with HR-HPV infection among Thai pregnant women. Materials and Methods: This cross-sectional study was conducted at the HRH Princess Maha Chakri Sirindhorn Medical Center from May 1, 2022 to January 31, 2023. The data were collected through primary HPV testing, liquid-based cytology (LBC), and a questionnaire. Results: Overall, 188 pregnant women participated in the study. The mean age was 28.91 years old. The prevalence of HPV infection was 12.7% (24/188), and the two most common types were HPV 52 (6/188, 3.1%) and HPV 16 (5/188, 2.66%). No case of HPV type 18 infection was detected. Abnormal cervical cytology smears were detected in 21 samples (11.17%). The women who had multiple partners had a significantly higher risk of HR-HPV infection compared to the group who had only a single partner (p < 0.05). Conclusion: The prevalence of HR-HPV infection during pregnancy in Thai women was 12.7%. Having multiple partners was found to be the greatest risk factor in this study. Primary HPV testing at a prenatal visit may be an option to improve screening coverage and could be considered in future cervical cancer screening programs.